Click here for free access to our latest coronavirus/COVID-19 research, commentary, and news.

Support nonprofit science journalism

Science’s extensive COVID-19 coverage is free to all readers. To support our nonprofit science journalism, please make a tax-deductible gift today.

Webinar Technology

New technologies for translational research: Applying high-content screening in cancer research and personalized medicine

This webinar is brought to you by the Science/AAAS Custom Publishing Office

New technologies for translational research: Applying high-content screening in cancer research and personalized medicine

Recorded 16 April 2015



New techniques and technologies are constantly being introduced that deepen our understanding of disease and therapeutic pathways. Biochemical screening methods have long been used in drug discovery labs, and more recently also in academic settings.  Recent advances in both imaging technology and high throughput automation have led to the development of high-content screening (HCS) and integrated liquid handling systems that have broad application in academia and industry. These advances in image acquisition and automation have transformed numerous fields and have yielded increased data capture and throughput. This webinar will discuss how integrated HCS imaging systems that have been coupled with novel computer modeling are being applied to systems biology, translational cancer research, and personalized medicine.

During the webinar, our panelists will:

  • Provide an overview of available integrated HCS technologies
  • Discuss the use of machine learning models (deep learning) in cancer research
  • Describe new approaches in personalized cancer research based on HCS
  • Answer questions from webinar viewers live and in real time!

The webinar will last approximately 60 minutes.

To learn more about products or technologies related to this webinar, go to:

Speaker bios

Rune Linding, Ph.D.

University of Copenhagen
Copenhagen, Denmark

Dr. Linding completed his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, followed by postdoctoral training at EMBL. He then jointly trained with professors Tony Pawson and Mike Yaffe at the Lunenfeld at Mount Sinai Hospital in Toronto, Canada, and the Massachusetts Institute of Technology (MIT) in Cambridge, US, respectively. Dr. Linding then established his own laboratory of Cellular & Molecular Logic at the Institute of Cancer Research (ICR) in London, UK, before returning to Denmark to take a position as professor of cellular signal integration at the Technical University of Denmark. In 2014, Dr. Linding moved his laboratory to the Biotech Research and Innovation Centre (BRIC) at University of Copenhagen where he is currently professor of cellular signaling. His research group focuses on big data network biology, exploring biological systems by developing and deploying algorithms aimed to predict cell behavior, in particular looking at cellular signal processing and decision making. A strategic focus is to continue to develop computational tools (such as KinomeXplorer, NetworKIN, and NetPhorest) and to deploy these on genome-scale quantitative data obtained by, for example, mass spectrometry, genomic, and phenotypic screens to understand the principles of how spatio and temporal assembly of mammalian signaling networks transmit and process information at a systems level in order to alter cell behavior. His overarching aim is to advance network medicine by identifying and targeting signaling networks associated with complex diseases. To this end Dr. Linding is currently leading high-level, strategic, multidisciplinary studies of signaling network dynamics driving cancer metastasis in collaboration with other labs at Harvard, Yale, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, MIT, and BRIC.

Stefan Kubicek, Ph.D.

Austrian Academy of Sciences
Vienna, Austria

Dr. Kubicek studied synthetic organic chemistry for his undergraduate degree at the Vienna University of Technology and the Swiss Federal Institute of Technology, and received his Ph.D. in in molecular biology at the Research Institute of Molecular Pathology in Vienna. This was followed by postdoctoral work with Stuart Schreiber at the Broad Institute of Harvard and MIT in Boston, Massachusetts in the U.S. Since 2010, Dr. Kubicek has headed the Platform Austria for Chemical Biology (PLACEBO), which provides chemical biology technologies, including high throughput screening and chemical proteomics, to the scientific community. In 2013, he became head of the Christian Doppler Laboratory for Chemical Epigenetics and Anti-Infectives, a public-private partnership between CeMM, Boehringer Ingelheim, and Haplogen. His research focuses on chromatin, epigenetics, and small molecules to change cell fates, with a particular focus on generating new insulin-producing beta cells from other cell types.

Giridharan Periyasamy, Ph.D.

Genome Institute of Singapore

Dr. Periyasamy is a platform head at the Centre for High Throughput Phenomics (CHiP-GIS) at the Genome Institute of Singapore. His research focuses on the cancer biology, drug resistance, and signaling pathway networks of human diseases as well as on ways to model these disorders. His current specific interest is the elucidation of novel mechanisms of drug resistance through the discovery/identification of novel gene function(s) and phenotypes using RNAi-mediated gene silencing or cDNA overexpression. He is also developing a robust and comprehensive panel of 3-D cell culture models from patient-derived primary cells that can be used to characterize different disease phenotypes and investigate the chemo-response of cells to novel or known drugs. The hope is that this work can lead to the establishment of an array of next generation preclinical 3-D tissue models for predictive toxicology screening and validation. Prior to his current position, Dr. Periyasamy worked as a scientific director of the HTS/HCS Screening Core Facility at the National Centre for Biological Sciences in India and was a group leader at Piramal Life Sciences in Mumbai, India. He studied at the Centre for Biotechnology at Anna University in Chennai, India, where he obtained his Ph.D. in biotechnology.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here